One dose of 1ml contains :
|Influenza A/equi-2/Kentucky/94 [H3N8] recombinant Canary pox virus (vCP 1529||) > 6.5 log 10 FAID50|
|Influenza A/equi-2/Newmarket/2/93 [H3N8] recombinant Canary pox virus (vCP 1533||) > 6.5 log 10 FAID50|
* vCP content checked by global FAID50 (fluorescent assay infectious dose 50%) and qPCR ratio between vCP.
The vaccine strains vCP 1529 and vCP 1533 are recombinant canary pox viruses expressing the haemagglutinin HA gene from the equine influenza virus strains A/equi-2/Kentucky/94 (American strain) and A/equi-2/Newmarket/2/93 (European strain), respectively. After inoculation, the viruses do not multiply in the horse but express the protective proteins. Consequently, these components induce immunity against equine influenza virus (H3N8) 14 days after primary vaccination course.